Work

Utility and real-world clinical outcomes of next-generation sequencing in advanced non-small-cell lung cancer in the South Indian population

Year: 2025

Type: article

Abstract: BACKGROUND: Next-generation sequencing (NGS) is an advanced sequencing technology that enables rapid sequencing of numerous DNA strands and performs simultaneous analysis of various genes and diverse genomic characteristics. While there is a lack of substantial evidence available, the extent to which NGS may improve clinical outcomes among cancer patients in a real-world scenario remains uncertain. OBJECTIVE: To investigate the clinical utility of NGS in patients treated with advanced non-small cell lung cancer (NSCLC) and its impact on real-world clinical outcomes, treated with targetable or non-targetable agents. MATERIALS AND METHODS: This was a prospective observational study conducted in 322 participants distributed over 2 broad categories- NGS and non-NGS. The NGS category consisted of patients who underwent genetic mutation screening by the NGS method. This group was further categorized into 2 subgroups-NGS-targetable and NGS-non-targetable. The non-NGS category consisted of patients who did not undergo mutation testing by the NGS method. RESULTS: There was a significant difference in overall survival between NGS and non-NGS groups (P = .0038). There was a significant difference between NGS targetable and non-targetable groups in terms of progression-free survival (PFS; P = .0016) and overall survival (OS; P < .0001). There was a significant difference between NGS-matched and non-matched groups in terms of PFS (P < .00011) as well as OS (P < .0001). CONCLUSIONS: NGS significantly improved survival in advanced NSCLC. Patients who received treatments matched to their NGS results experienced significantly longer survival compared to those with non-matched treatments.

Source: The Oncologist

DOI: 10.1093/oncolo/oyaf168

Authors: Thattungal Manoharan Anoop, Lakshmi Raj, Pallavi Nair, Athira Vincent

Institution: Regional Cancer Center, Thiruvananthapuram

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,852